The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy

James T Wu1, John G Kral

  • 1Department of Surgery, SUNY Downstate Medical Center, Brooklyn, New York, USA. jtwu@bcm.tmc.edu

Insights

Nuclear factor kappaB (NF-kappaB) is crucial in cancer development. Aberrant NF-kappaB activity drives breast cancer progression and metastasis, suggesting NF-kappaB inhibition as a potential therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Nuclear factor kappaB (NF-kappaB) is a key transcription factor superfamily involved in eukaryotic gene regulation.
  • NF-kappaB signaling pathways are implicated in critical cellular processes including proliferation, apoptosis, and cell-cycle control.
  • Dysregulation of NF-kappaB is increasingly recognized for its role in various cancers, particularly breast cancer.

Purpose of the Study:

  • To review the regulatory mechanisms and physiological significance of NF-kappaB activation in carcinogenesis.
  • To highlight the role of NF-kappaB in mediating mammary gland carcinogenesis.
  • To discuss the potential of NF-kappaB as a therapeutic target in breast cancer.

Main Methods:

  • Literature review of studies on NF-kappaB signaling pathways.
  • Analysis of the role of NF-kappaB in cell proliferation, apoptosis, and cell-cycle control.
  • Examination of NF-kappaB expression in relation to breast cancer progression and metastasis.

Main Results:

  • NF-kappaB regulates critical cellular processes that, when uncontrolled, contribute to cancer development.
  • Aberrant NF-kappaB activity is linked to breast cancer progression and may predict metastatic potential.
  • Constitutive NF-kappaB expression suggests its integral role in mammary carcinogenesis.

Conclusions:

  • NF-kappaB is a significant mediator of mammary carcinogenesis.
  • Targeting NF-kappaB signaling presents a promising novel therapeutic strategy for breast cancer.
  • Understanding NF-kappaB regulation is vital for developing effective adjuvant therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...